27/12/2006 11:38 MARKET TALK: SkyePharma Management Needs To Prove Itself
1138 GMT [Dow Jones] SkyePharma (SKP.LN) management needs to repeatedly prove itself to the market for the shares to appreciate, says Credit Suisse. It continues to see the shares as undervalued following SkyePharma's announced financing agreement Wednesday with the market focused on the near term cash resources. It sees the divestment of the injectables business, expected by y/e '06, as the last step in the process following the Flutiform partnerships with Kos in May '06 and Mundipharma in Sept '06. "Investment in the story remains a call on management's ability to deliver," it adds. Shares trade -2.8% at 26p. (KHO) Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com
Scpie stock quotes
Scpie stock charts
Follow this thread
